ADC Ther­a­peu­tics nabs its first ap­proval as FDA of­fers a quick OK for its DL­B­CL can­cer treat­ment

The FDA won’t be wait­ing around for the PDU­FA date for its lat­est OK on the can­cer front.

Reg­u­la­tors came through with an ac­cel­er­at­ed ap­proval for ADC Ther­a­peu­tics’ lon­cas­tux­imab tesirine-lpyl as a third-line ther­a­py for dif­fuse large B-cell lym­phoma, which was ba­si­cal­ly a shoe-in look­ing for an OK in drug re­sis­tant pa­tients with a pri­or­i­ty re­view at­tached to the ap­pli­ca­tion.

This CD-19 an­ti­body drug con­ju­gate will now be sold as Zyn­lon­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER